amgen

Among leading biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw significant percentage declines in short interest between the July 31 and August 15 settlement dates. Short sellers also shied away...

On Sunday, after months of trying to work out a deal, Amgen (NASDAQ: AMGN) and Onyx (NASDAQ: ONXX) announced that Amgen will acquire Onyx for $125 per share valuing the deal as $10.4 billion. The announcement is about as much of a surprise as those two flirtatious coworkers that later told...

The oil and gas industry will be well represented on this week's earnings stage, with reports due from supermajors Exxon Mobil (NYSE: XOM) and Chevron (NYSE: CVX), and many others in the field. Viacom (NYSE: VIAB) and Comcast (NASDAQ: CMCSA) will be the highlights among the various media companies...

Among biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Onyx Pharmaceuticals (NASDAQ: ONXX) and Pharmacyclics (NASDAQ: PCYC) saw the most significant percentage declines in short interest between the June 28 and July 15 settlement dates. Short sellers also shied away from...

Among biotech and emerging pharmaceutical companies, Gilead Sciences (NASDAQ: GILD) and Onyx Pharmaceuticals (NASDAQ: ONXX) saw the most significant rises in short interest between the June 14 and June 28 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Arena...

Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest between the May 31 and June 14 settlement dates. The number of shares sold short in Onyx Pharmaceuticals (NASDAQ: ONXX), Pharmacyclics (NASDAQ: PCYC) and Regeneron...

This past weekend in Barron's online: the midyear 2013 roundtable, and the prospects for Eastman Chemical, BB&T, Amgen and Big Lots. Cover Story "Shifting Winds" by Lauren R. Rublin. The investment experts in Barron's Midyear Roundtable explain the risks and explore the opportunities as an...

Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), saw the most significant rise in short interest between the May 15 and May 31 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Dendreon (NASDAQ: DNDN), Onyx Pharmaceuticals (NASDAQ: ONXX)...

Among biotech and emerging pharmaceutical companies, Regeneron Pharmaceuticals (NASDAQ: REGN) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw he most significant rise in short interest between the April 30 and May 15 settlement dates. The number of shares sold short in Alexion Pharmaceuticals (...

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the latter two weeks of April. The number of shares sold short in Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX) and VIVUS (NASDAQ: VVUS)...

The research team at PropThink, which focuses on emerging growth companies in the health care sector, recently offered a list of bargain biotech stocks worth a look. The stocks that made the list include Endo Health Solutions (NASDAQ: ENDP), Illumina (NASDAQ: ILMN) and Keryx Biopharmaceuticals (...

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the first two weeks of April. The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD...

Amgen (NYSE: AMGN), shares of which reached a multiyear high Monday, is scheduled to report its first-quarter 2013 results Tuesday, April 23, after the markets close. Investors will be keeping an eye on the impact that a recent German regulatory review of drug prices may have on the company over...

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of March. The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena Pharmaceuticals (NASDAQ: ARNA), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX), Vertex...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of March. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between the...